Amgen (AMGN) Reports Q4 Beat
Tweet
Share
E-mail_58cbc46cd3c33.jpg)
Get Alerts AMGN Hot Sheet
Price: $437.23 --0%
EPS Growth %: +2.7%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
CAN, UNFI, SUNB, More
EPS Growth %: +2.7%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) reported its Q4 results, with EPS coming in at $4.36, beating the consensus estimate of $4.12. Revenue grew 3% year-over-year to $6.85 billion, slightly missing the consensus estimate of $6.88 billion, driven by increased Other Revenue from the Eli Lilly and Company COVID-19 manufacturing collaboration.
Total product sales for Q4 decreased 1% year-over-year. Unit volumes increased 7% but were more than offset by lower net selling price and lower inventory levels.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Downgrades Amgen (AMGN) to Market Perform
- Ciena (CIEN) Tops Q3 EPS by 39c, Offers Guidance
- Toro Company (TTC) Tops Q3 EPS by 3c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
